This content is in French.
Castration-resistant metastatic prostate cancer and first-line treatments
21 mai 2024
Prostate cancer is the most common cancer in men over 50. Currently, the overall survival of a patient with castration-resistant metastatic prostate cancer is estimated at 36 months.
Current first-line therapeutic approaches to this cancer include antiandrogens with abiraterone and chemotherapy with docetaxel and cabazitaxel.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Zhang D, Weng H, Zhu Z, Gong W, Ma Y. Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review. Front Oncol. 2024 Apr 15;14:1378993. doi: 10.3389/fonc.202
View the source
